September 16, 2022 | BOTOX® Cosmetic, Daxxify neurotoxin
Daxxify neurotoxin recently FDA-approved for frown line treatment
Biotechnology company Revance issued a press release this month announcing the FDA approval of Daxxify (DaxibotulinumtoxinA-Ianm) for the treatment of frown lines. Findings from clinical trials using Daxxify found the average duration of action of the neurotoxin at approximately 6 months, compared to 3~4 months of other neurotoxins, such as Botox and Dysport, while enjoying a similar safety profile. This is very […]
Read More
